

Reference: FOI.ICB-2526/217

Subject: Commissioning and Activity Data for GLP-1 Weight-loss Medicines

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
1. Commissioning status - As of today, does the ICB commission GLP-1 medicines for adult weight management (examples include semaglutide/Wegovy, tirzepatide/Mounjaro)? (Answer: Yes/No). If yes, please give the date commissioning began.	Yes, the following were approved to prescribe on BNSSG Joint Formulary: • Liraglutide as per NICE TA664 March 21 • Semaglutide as per NICE TA875 June 23 • Tirzepatide as per NICE TA1026 Dec 25 for specialist weight management services • Tirzepatide as per NHS England interim commissioning guidance in primary care July 25
2. Tier-3 services - Do you currently commission a Tier-3 (specialist) weight-management service for adults? (Yes/No). If yes, how many Tier-3 clinics do you commission in the ICB and what is the current waiting list length (number of patients) as at 07/10/2025?	Yes. The ICB commissions three Tier-3 clinics delivered by North Bristol NHS Trust (NBT, Oviva Ltd and Nuffield. The ICB does not hold waiting list length as at 07/10/25. We advise you to contact the providers directly who may hold this information. • NBT: Freedom of Information Act 2000 North Bristol NHS Trust • Oviva: https://oviva.com/uk/en/contact/

	Nuffield: https://www.nuffieldhealth.com/hospitals/bristol#contact-us-form
3. Typical aftercare/follow-up - For patients started on GLP-1 medicines under your commissioning, please provide the standard follow-up entitlement (e.g. number of dietitian sessions per patient, psychology sessions, exercise referral, nurse review frequency).	Tirzepatide in BNSSG Primary Care Wraparound care (health coaching) for patients prescribed Tirzepatide in primary care is commissioned nationally by NHS England. 13 sessions over 9-month programme. Please contact NHS England for more information: england.contactus@nhs.net A tirzepatide prescribing review undertaken by a suitably qualified healthcare professional in year 1 should occur monthly for 6 months and then at 12 months. The model for year 2 and beyond is in development. For secondary care, patients are offered the opportunity to partake in a 2 year programme with Specialist Weight Management Services offering the full programme of a support. This programme does not specify a maximum number of dietitian sessions etc and patients will be offered support based on their clinical need whilst part of the programme.

The information provided in this response is accurate as of 20 October 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.